PDCD1 and neoplasm: In addition to summarizing the classic mechanisms underlying PD‐1/PD‐L1 blockade enhancement, a few cutting‐edge mechanisms for overcoming resistance to anti‐PD‐1/PD‐L1 therapy by IFN‐α/β are discussed in this review, including stimulation of the cGAS‐STING‐IFN‐I axis, activation of tumor immunogenicity and immune cells, modulation of the TME, induction of ICD, and upregulation of PD‐L1 expression.